Cardiff Oncology Employee Directory
Biotechnology ResearchCalifornia, United States51-200 Employees
Cardiff Oncology is a clinical-stage biotechnology company in the biotechnology research industry, headquartered in San Diego, California. The company focuses on developing oncology therapies by inhibiting PLK1, with its lead asset onvansertib, a PLK1 inhibitor. Onvansertib is being evaluated in combination with standard-of-care therapies in clinical programs for KRAS/NRAS-mutated metastatic colorectal cancer and metastatic pancreatic ductal adenocarcinoma, with investigator-initiated trials in triple negative breast cancer and small cell lung cancer. The programs aim to target tumor vulnerabilities to overcome resistance and to improve outcomes relative to standard-of-care. The company employs between 51 and 200 people and, in April 2026, appointed Mani Mohindru as President and Chief Executive Officer.